Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (<1% in hospitals in the USA to about 20% in a British hospital). Mortality related to these nosocomial SARS-CoV2 infections is higher than in the general population. The risk factors identified for this nosocomial acquisition are multiple. We were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement.

The objectives of this study are to determine the proportion of nosocomial SARS COV 2 infections in the total number of patients hospitalized with a Covid-19 infection at the CHR Metz-Thionville in 2021, and to describe the characteristics of this population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SARS CoV 2 Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHR Metz-Thionville/Hopital de Mercy

Metz, 57085, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients hospitalised at the CHR Metz-Thionville in medicine, surgery and obstetrics (MCO) or geriatric follow-up and rehabilitation care (SSR) units, in 2021 for a Covid-19 infection defined by the existence of a positive PCR result for SARS-CoV2 during the stay, or by the existence of an ICD10 code for COVID in the PMSI data of the health care establishment

Exclusion criteria

Opposition to participate in the study after reading the patient information note.

Treatment and study plan

Nosocomial SARS-COV 2 Infection proportion

Other

Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Primary outcomes

Proportion of hospital-acquired infections in patients hospitalised with a covid-19 infection

Time frame: up to 8 months after the third COVID-19 wave

Several elements are taken into account: a) the time between entry into the establishment and the first positive SARS COV 2 PCR, b) the time between entry into the establishment and the appearance of the most frequent symptoms (fever, cough), if present in the patient, in the seven days preceding the first positive SARS COV 2 PCR, c) the existence of an epidemiological link with other infected patients, via contact in a double room with another case, and/or via hospitalisation in a department concerned by a cluster situation according to the Santé Publique France definition of May 2020 (identified on the basis of monitoring and surveillance data from the hygiene department).

Secondary outcomes

Description of the nosocomial infected population

Time frame: up to 8 months after the third COVID-19 wave

age, sex, hospital unit care, outcomes of stay, vaccination status, associated conditions (comorbidities according to Charlson score, obesity, pregnancy), existence of screening on admission, time to acquisition of nosocomial infection, number of negative SARS-COV 2 PCRs in the institution before the first positive PCR, type of variant, presence of symptoms (cough, fever), stay in a double room in the 14 days prior to infection, cluster status in the ward, length of stay after infection.

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Régional Metz-Thionville

Other

Registry information

Official study title

Proportion of Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

Acronym: COVIDIN

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Oct 5, 2022
Registry last updated: May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed